Background: To analyse trends in incidence, survival and risk of second neoplasms following vaginal and vulvar cancers using data collected by the Swiss Cancer Registry of Vaud over the 21-year period 1974-1994.
Introduction
Cancers of the vagina and vulva are rare neoplasms, accounting for less than 1% of all cancers in women, and 9% of female genital tract neoplasms [1] .
Most information on descriptive epidemiology of these neoplasms comes from the Surveillance Epidemiology and End Results (SEER) Program of the US National Cancer Institute [2, 3] . The SEER data over the period [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] showed no appreciable change over time for vaginal and invasive vulvar cancer, with age-standardized incidence rates (on the US population) around 1.0 and 1.5/100,000, respectively. In contrast, the incidence rate of in situ vulvar cancer nearly doubled between 1973 and 1987, the rise being particularly marked below age 55 [2] . Five-year relative survival was over 90% for vulvar cancers, and less than 50% for vaginal neoplasms [3] . Selected clinical series [4] gave five-year survival of about 60% for vulvar and 50% for vaginal carcinomas. An excess of secondary primary cancers after vulvar and vaginal cancers was found for smoking or human-papillomavirus (HPV) related neoplasms [5] . A significant excess of invasive vulvar cancer following vulvar intra-epithelial neoplasia was also reported [6] .
Most other data come from hospital-based series. They confirmed an increase of intra-epithelial vulvar neoplasia, mostly at younger age [7] [8] [9] [10] . These trends have been associated to changed sexual habits in most recent cohorts of women, infection with HPV, and smoking [11] [12] [13] .
To provide further, population-based information on incidence, survival and second neoplasms following vaginal and vulvar cancers, we analysed data from the Cancer Registry of Vaud over the 21-year period 1974-1994.
Materials and methods
Vulvo-vaginal cancer incidence data for the period 1974-1994 were abstracted from the Vaud Cancer Registry file, which includes data concerning incident cases of malignant neoplasms in the Canton (whose population according to the Census 1990 was about 580,000 inhabitants) [1] .
Information collected by the register includes general demographic characteristics of the patient (age, sex, municipality of residence), site and histological type of the tumour according to the International Classification of Diseases for Oncology [14] , and time of diagnostic confirmation.
The present series comprises 257 invasive vulvo-vaginal cancer primaries (ICD-0 T: 184.0, vagina, n = 69; 184.1-184.4, vulva, n = 153; 184.8-184.9, non specified lower genital tract neoplasms, n = 35) registered during the 21 year period from 1974 to 1994. Ninety-five histologically verified in situ vulvo-vaginal neoplasms were also registered (85 for the vulva; 56% being labeled as Bowen's disease). Histo- logical confirmation was performed in over 92% of the invasive neoplasms, and only 2.5% were discovered at death. Age-standardized incidence rates (by the direct method, world standard population) were computed for the population of all ages and for three separate age groups (20-44,45-64 and 65 or more years). Mean annual percent changes were derived from standard log-linear regression models.
Information on survival was derived from mortality statistics and, for 'apparently' non-deceased cases, through an active follow-up based on verification of vital status from registries of current residence [14] . Patients who migrated outside the Canton, and were therefore not traceable (2.3%), were censored at the date of emigration. The vital status of each registered case has thus been verified up to June 30th, 1997. One-, three-, five-and 10-year relative survival estimates were computed after allowance for the general lifetables of the Canton [15] Invasive and in situ cases were followed-up to 31 December 1996 for the occurrence of second primary neoplasms, for a total of 1,502 person-years at risk (918 for invasive neoplasms). Calculation of expected numbers of cases were based on site-, age-and calendar period-specific incidence rates, multiplied by the corresponding number of person-years at risk. The significance of the observed: expected ratios (standardized incidence ratio (SIR)) and their corresponding 95% confidence intervals (95% CI) was based on the Poisson distribution [16] .
Results
Over the period 1974-1994, 257 vulvo-vaginal invasive cancers were registered. Of these, 69 were vaginal neoplasms (51, 74% squamous cell), 153 vulvar cancers (114, 75% squamous cell) and 35 were non specified lower genital tract neoplasms. A total of 94 in situ neoplasms were also registered; of them, 85 were from the vulva. Table 1 gives the age-standardized (world standard) incidence rates in two separate calendar periods (1974-1984; 1985-1994) . Incidence of invasive vaginal cancer decreased from 0.8 to 0.4/100,000 women, while invasive vulvar cancer remained approximately stable (1.1 in 1974-1984; 1.3 in 1985-1994) . Other invasive lower female genital tract neoplasms declined from 0.3 to 0.1/100,000. In contrast, some rise was observed for in situ vaginal cancers (from 0.08 to 0.1/100,000 women) and for in situ vulvar cancers (from 0.8 to 1.3/100,000). The estimated percent annual changes were -3.7% and +2.6% for invasive neoplasms of vagina and vulva, respectively, and +1.2% and +5.1% (P -0.05) for vaginal and vulvar in situ neoplasms. Table 2 gives corresponding figures in three separate age groups (20-44,45-64, ^65 years). While the decline for invasive vaginal cancer was observed both at age 45 to 64 and in elderly women, the rise for in situ vulvar cancer was larger below age 45, and under age 65 there was also some increase in invasive vulvar cancers.
Survival rates are plotted in Figure 1 (for invasive neoplasms) and given in Table 3 in terms of relative survival. These were 41% at 10 years for invasive vaginal cancer, 48% for invasive vulvar cancer, and 94% for in situ vulvar neoplasms.
Observed and expected numbers of second neoplasms following vaginal and vulvar neoplasms are given in Table 4 . Excess rates were observed for oro-pharyngeal cancers following invasive vulvar and vaginal cancers (two observed, 0.2 expected; SIR = 10.3), and for tobaccorelated neoplasms (oro-pharyngeal and lung) following combined invasive and in situ vulvar and vaginal cancers (seven observed, 0.8 expected; SIR = 9.0; 95% CI: 3.6-18.5). Furthermore, there was a significant excess of invasive vulvar cancer following in situ cancer (four observed, 0.03 expected). Rates were also significantly above unity for non-melanomatous skin cancer follow- excess was observed for colorectal cancer (five observed, 1.7 expected; SIR = 3.0) following invasive vulvo-vaginal cancer.
Discussion
The incidence rates of invasive and in situ vulvar and vaginal neoplasms in this European population were of similar magnitude as those reported from the SEER Program in the United States [2, 3, 18, 19] and also trends in incidence were in the same direction, with some decline in vaginal cancer, but a rise in vulvar cancer, mostly at younger age and for in situ neoplasms. Likewise, the five-and 10-year survival rates (over 90% for in situ neoplasms, less than 50% for invasive vaginal and vulvar neoplasms) are well comparable with available data from the SEER Program [2, 3, 17, 18] and clinical series [4, [7] [8] [9] [10] .
The data were derived from a population-based cancer registry system established for over 20 years, and adopting the same criteria of registration for invasive and in situ vulvo-vaginal neoplasms [1] . A limitation of the study, however, is given by the small number of cases, particularly for in situ vaginal neoplasms.
The main interest and importance of this dataset is therefore in confirming, on the basis of a populationbased series from Europe, a number of clinical observations [7] [8] [9] [10] suggesting a rise in (in situ) vulvar cancers.
This finding has been usually related, as for cervical cancer [19] , to the changed sexual habits of younger generations of women, and possibly to infection with HPV [12, 13] . This hypothesis is supported by the excess oral cancer following vulvo-vaginal cancers, since a role of HPV on oral carcinogenesis has also been postulated [20] . HPV has also been related to non-melanomatous skin cancer [21, 22] , although the issue remains open to discussion. Likewise, the excess of lung, oral and other tobacco-related neoplasms following vulvo-vaginal neoplasms supports a role for cigarette smoking, as reported in case-control investigations [23] [24] [25] .
The decline in invasive vaginal cancer, mostly in middle and elderly age, is more difficult to explain, but may be related to the increased frequency of Pap-smear, as reflected by the fall in invasive cervical cancer observed in the same population [26] .
